Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials

Recurrent microsatellite stable (MSS) endometrial cancer has poor response to conventional therapy and limited efficacy with immune checkpoint monotherapy. We conducted a retrospective study of recurrent MSS endometrial cancer patients enrolled in immunotherapy-based clinical trials at MD Anderson C...

Full description

Bibliographic Details
Main Authors: Jeffrey A. How, Amir A. Jazaeri, Siqing Fu, Jordi Rodon Ahnert, Jing Gong, Bettzy Stephen, Hanna Ferreira Dalla Pria, Priya Bhosale, Amber Johnson, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
immunotherapy
immune checkpoint inhibitors
endometrial cancer
microsatellite stable
clinical trials
Online Access:https://www.mdpi.com/2072-6694/14/15/3695

Internet

https://www.mdpi.com/2072-6694/14/15/3695

Similar Items